YKL-40 - an emerging biomarker in cardiovascular disease and diabetes

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Rathcke, Camilla N ^a   Vestergaard, Henrik ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG; AUTACOID; CHI3L1 PROTEIN, HUMAN; LECTIN;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; ATHEROSCLEROSIS; BLOOD; DIABETIC ANGIOPATHY; IMMUNOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; INFLAMMATION MEDIATORS; LECTINS; RISK ASSESSMENT; RISK FACTORS;

EID: 71949101822     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-61     Document Type: Review

References (55)

1. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004, 110:380-385. 10.1161/01.CIR.0000136581.59584.0E, 15262834.
2. Libby P, Willerson JT, Braunwald E. C-reactive protein and coronary heart disease. N Engl J Med 2004, 351:295-298. 10.1056/NEJM200407153510318, 15257564.
3. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004, 116(Suppl 6A):9S-16S. 10.1016/j.amjmed.2004.02.006, 15050187.
4. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38. 10.1373/clinchem.2007.097360, 18160725.
5. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993, 268:25803-25810.
6. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995, 270:13076-13083. 10.1074/jbc.270.22.13076, 7768902.
7. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39(CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997, 43:221-225. 10.1006/geno.1997.4778, 9244440.
8. Hauschka PV, Mann KG, Price P, Termine JD. Report of the Ad Hoc Committee on Nomenclature and Standards for Bone Proteins and Growth Factors. J Bone Miner Res 1986, 1:485-486.
9. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev 2006, 15:194-202. 10.1158/1055-9965.EPI-05-0011, 16492905.
10. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003, 278:37753-37760. 10.1074/jbc.M303137200, 12851408.
11. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006, 53:172-209.
12. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998, 251:504-509. 10.1046/j.1432-1327.1998.2510504.x, 9492324.
13. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995, 270:26252-26256. 10.1074/jbc.270.5.2198, 7592832.
14. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 2006, 55:221-227. 10.1007/s00011-006-0076-y, 16955240.
15. Kirkpatrick RB, Matico RE, McNulty DE, Strickler JE, Rosenberg M. An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 1995, 153:147-154. 10.1016/0378-1119(94)00756-I, 7875581.
16. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 1996, 60:540-545.
17. Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, Berheijden G, Miltenburg AM, Rijnders AW, Veys EM, de Keyser F. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000, 43:1233-1243. 10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9, 10857782.
18. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, Krause SW. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003, 278:44058-44067. 10.1074/jbc.M306792200, 12933821.
19. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003, 287:79-87. 10.1016/S0014-4827(03)00069-7, 12799184.
20. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999, 250:168-173. 10.1006/excr.1999.4511, 10388530.
21. Johansen JS, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I, Price PA. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 1999, 42:2624-2630. 10.1002/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K, 10616010.
22. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999, 19:687-694.
23. Johansen JS, Hoyer PE, Larsen LA, Price PA, Mollgard K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007, 55:1213-1228. 10.1369/jhc.7A7245.2007, 17712177.
24. Ringsholt M, Hogdall EV, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol 2007, 38:33-43. 10.1007/s10735-006-9075-0, 17242979.
25. De CF, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40(cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001, 285:926-931. 10.1006/bbrc.2001.5253, 11467840.
26. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39(HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002, 365:119-126. 10.1042/BJ20020075, 1222662, 12071845.
27. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA. Role of breast regression protein 39(BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009, 206:1149-1166. 10.1084/jem.20081271, 2715037, 19414556.
28. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004, 380:651-659. 10.1042/BJ20040099, 1224214, 15015934.
29. Recklies AD, Ling H, White C, Bernier SM. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005, 280:41213-41221. 10.1074/jbc.M510146200, 16234240.
30. Johansen JS, Lottenburger T, Nielsen HJ, Jensen JE, Svendsen MN, Kollerup G, Christensen IJ. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008, 17:2603-2608. 10.1158/1055-9965.EPI-07-2766, 18843001.
31. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006, 55:53-59. 10.1007/s00011-005-0010-8, 16612564.
32. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H. Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 2009,
33. Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss. Obes Surg 2009, 19(11):1557-63. 10.1007/s11695-009-9917-4, 19633900.
34. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation?. Europace 2009, 11:1032-1036. 10.1093/europace/eup103, 19411674.
35. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007, 18:391-396. 10.1097/MCA.0b013e328241d991, 17627189.
36. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, Bindslev L, Haack-Sorensen M, Jorgensen E, Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008, 42:295-302. 10.1080/14017430802220567, 18615353.
37. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, Krogh-Madsen R, Taudorf S, Lindegaard B, Pedersen BK. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008, 57:3078-3082. 10.2337/db08-0182, 2570404, 18650368.
38. Johansen JS, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008, 151:260-266. 2276948, 18070151.
39. Kralisch S, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007, 7:39-45. 10.2174/138955707779317821, 17266636.
40. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107:690-695. 10.1161/01.CIR.0000049742.68848.99, 12578870.
41. Millis AJ, Hoyle M, Reich E, Mann DM. Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem 1985, 260:3754-3761.
42. Millis AJ, Hoyle M, Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986, 127:366-372. 10.1002/jcp.1041270304, 3086326.
43. Schwartz SM. Smooth muscle migration in vascular development and pathogenesis. Transpl Immunol 1997, 5:255-260. 10.1016/S0966-3274(97)80005-6, 9504144.
44. Fach EM, Garulacan LA, Gao J, Xiao Q, Storm SM, Dubaquie YP, Hefta SA, Opiteck GJ. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004, 3:1200-1210. 10.1074/mcp.M400160-MCP200, 15496433.
45. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjoller E, Kolmos HJ, Lind I, Nielsen H, Gluud C. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009, 30:1066-1072. 10.1093/eurheartj/ehp049, 19270316.
46. Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008, 19:257-263. 10.1097/MCA.0b013e3282f40dd5, 18480670.
47. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444. 10.2337/diacare.16.2.434, 8432214.
48. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999, 19:1992-1997.
49. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426. 10.1001/jama.286.4.421, 11466120.
50. Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 2005, 68:1446-1450. 10.1111/j.1523-1755.2005.00556.x, 16164620.
51. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waughn NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765. 10.1007/s00125-003-1116-6, 12774166.
52. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009, 32:323-328. 10.2337/dc08-1144, 18957531.
53. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009, 511:159-184. full_text, 19347297.
54. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barjer FG, Fuller GN, Aldape KD. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006, 12:3935-3941. 10.1158/1078-0432.CCR-05-2202, 16818690.
55. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009,